Biologics US 2025
Learn about our novel Path to IND for biologics, which takes you from DNA
to first-in-human Phase I clinical trials in just nine months*.
October 2–3, 2025 | San Diego, CA | Booth #23
About Biologics US 2025
Biologics US 2025 offers an opportunity to explore the next generation of biologics research and development—from novel process and engineering strategies to enhance antibody function and production, to AI-driven antibody design and the optimization of complex molecules such as ADCs, bispecifics, and Fc-fusion proteins. This year’s revamped program will feature interactive sessions, networking opportunities, and exclusive expert-led talks.
Event details
Date: October 2–3, 2025
Format: In-person
Location: San Diego, California
Booth number: #23
Event website: https://oxfordglobal.com/
About Thermo Fisher Scientific
From early development through commercialization and beyond, Thermo Fisher Scientific provides a full suite of integrated CDMO and CRO services and solutions for large molecule therapeutics, namely biologic and cell and gene therapies.
At Biologics US 2025, we’re proud to present Path to IND for biologics—a cutting-edge platform designed by our in-house experts to address key challenges in biologics development for IgG, bispecific, and Fc-fusion-based biologics.
Visit our team at booth #23 to learn more or schedule a meeting.
Attend our panel discussion
“Strategic decisions in early R&D for antibody research and discovery”
Date: Thursday, October 2
Time: 4:15 – 5:05 p.m. (50 minutes)
Track: Antibody Discovery; Design & Engineering
Early R&D decisions are pivotal to the success of antibody development.
This panel brings together industry experts to discuss the latest advances in antibody engineering and design, and why partnering with CDMOs and CROs early—before final candidate selection—is essential.
Attend this panel to learn how integrating external expertise and scalable platforms from the start can help reduce risk while accelerating timelines and costs, ultimately streamlining your path to clinical success
Meet our industry expert
Paul Jorjorian
Vice President, Development & Scientific Solutions, Pharma Services, Thermo Fisher Scientific
Paul Jorjorian is responsible for leading R&D, process and analytical development, as well as MSAT strategy for our Drug Substance Division.
During his time at Thermo Fisher Scientific, Paul has been at the forefront of innovation—driving the implementation of our novel Path to IND for biologics platform and the integration of the 5,000 L HyPerforma™ DynaDrive™ Single-Use Bioreactor. These efforts have helped establish our state-of-the-art biologics development and commercialization site in St. Louis, MO, as the largest facility for single-use technology innovation in the US.
Prior to his current role, Paul has held multiple executive level roles in both operations and process development, making him a true connoisseur of biologic therapeutic production.
Join us at our booth on October 2 to meet Paul in person and discuss your biologic program—no matter what stage of research or development you're in.
Schedule a meeting
Our industry experts are looking forward to connecting at Biologics US 2025, but their calendars are expected to fill quickly. Pre-book a meeting now to secure your time with them.
Continuing education for the pharma industry
Follow us on social for event updates
We look forward to seeing you soon